Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pneumococcal Vaccines Market Snapshot: Pfizer And Merck Face Off

Executive Summary

Pfizer's Prevnar 20 and Merck's Vaxneuvance are launching simultaneously and are expected to help drive vaccines growth for both big pharmas.

You may also be interested in...



Vaxneuvance, Prevnar 20 Earn CDC Cmte Nod For Age- And Risk-Based Use; Broader Shingrix Use Supported

ACIP votes unanimously to recommend Merck and Pfizer’s pneumococcal vaccines in elderly and immunocompromised adults; GSK’s herpes zoster vaccine also gets unanimous nod for immunocompromised adults.

With Prevnar 20, Pfizer Aims To Maintain A Top Franchise

The successor to Pfizer’s 13-valent pneumococcal vaccine, a lynchpin of the company's lifecycle management strategy, was approved in the US.

Prevnar 13 Loses ‘Routine’ Endorsement For Older Adults In CDC Panel Vote

ACIP still supports use of Pfizer’s pneumococcal vaccine in immunocompetent individuals ages 65 years and older based on shared clinical decision-making, but concludes that routine immunization is no longer warranted due to herd effect from pediatric vaccination.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel